Form 4: ANI Pharma Executive Sells Shares Under 10b5-1 Plan

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., sold 400 shares of common stock at $98.42 per share under a pre-arranged trading plan.

Summary

• Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc. (ANIP), reported a sale of common stock.
• The transaction involved the disposition of 400 shares of ANIP common stock.
• The shares were sold at a price of $98.42 per share.
• The sale occurred on September 12, 2025.
• Following this transaction, Meredith Cook directly beneficially owns 76,074 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 17, 2024.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a common practice for executives to manage their equity holdings. It does not indicate any new positive or negative developments for the company.

Future Outlook

No forward-looking statements or guidance were provided in this insider transaction report.

Industry Context

This filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as it is a small, pre-planned sale by an executive, not indicative of a change in company fundamentals or management's confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled sale of a relatively small number of shares by an executive under a Rule 10b5-1 plan. Such transactions are common for executives to diversify their portfolios or for liquidity purposes and are not typically indicative of a change in the company's fundamental prospects or management's long-term confidence. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

ANI Pharmaceuticals, ANIP, Insider Trading, Form 4, Stock Sale, Meredith Cook, Rule 10b5-1, Executive Compensation